No profile data available.
Telix Pharmaceuticals Limited (TLX) is a healthcare company in the additional specific healthcare equipment industry, based in North Melbourne, Australia.
Its largest business segment, Precision Medicine, brought in 71% of segment revenue in fiscal year 2025; United States was the largest region with 98%. Its market capitalization was $3.27 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Precision Medicine, with 621.93 million AUD or 71% of segment revenue in fiscal year 2025. Next: Manufacturing Solutions (28%) and Therapeutics (1%).
United States: 98% of revenue by region in fiscal year 2025, followed by China (1%).
$3.27 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (additional specific healthcare equipment) include Align Technology, Inc. (ALGN), Haemonetics Corporation (HAE), Envista Holdings Corporation (NVST), Establishment Labs Holdings Inc. (ESTA).